Not applicableStudy completedNCT01935739What this trial is testingDiscordant HER2/Neu Status of Breast Cancer.Who this might be right forMalignant Neoplasm of Breast. National Cancer Institute, Thailand 105
Not applicableStudy completedNCT02535026What this trial is testingAn Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American ParticipantsWho this might be right forBreast Cancer Hoffmann-La Roche 580
Not applicableStudy completedNCT05217381What this trial is testingReal-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 StatusWho this might be right forEarly Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer MedSIR 18,533
Large-scale testing (Phase 3)Study completedNCT01942135What this trial is testingPalbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)Who this might be right forMetastatic Breast Cancer Pfizer 521
Not applicableNot Yet RecruitingNCT07132502What this trial is testingTreatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast CancerWho this might be right forBreast Cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences 24
Not applicableStudy completedNCT02371174What this trial is testingPost-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.Who this might be right forBreast CancerHER2-negative Breast Cancer Eisai Co., Ltd. 651
Not applicableUnknownNCT03947736What this trial is testingDynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCRWho this might be right forRecurrent or Metastatic Breast Cancer Chinese Academy of Medical Sciences 200
Not applicableStudy completedNCT02773784What this trial is testingComparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.Who this might be right forInvasive Breast Cancer Peking University 314
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07179939What this trial is testingMaintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyWho this might be right forHER2-positive Breast Cancer Fudan University 288
Not applicableEnded earlyNCT03197805What this trial is testingAssessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer PatientsWho this might be right forBreast Cancer Centre Jean Perrin 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322What this trial is testingDurvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Who this might be right forER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status UNICANCER 172
Early research (Phase 1)Study completedNCT01320592What this trial is testingPD0332991/Paclitaxel in Advanced Breast CancerWho this might be right forBreast Cancer Abramson Cancer Center at Penn Medicine 28
Testing effectiveness (Phase 2)WithdrawnNCT05664893What this trial is testingStudy to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)Who this might be right forHER2 Negative Breast Cancer Not Immediately Operated Centre Antoine Lacassagne
Not applicableNot Yet RecruitingNCT07758127What this trial is testingUpdates and Insights on HER2 in Breast Cancer in Sohag GovernorateWho this might be right forHER2 Status in Breast Cancer Sohag University 100
Post-approval studies (Phase 4)UnknownNCT01597999What this trial is testingBenefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast CancerWho this might be right forInvasive Breast Cancer Mahidol University 60
Testing effectiveness (Phase 2)Study completedNCT02860000What this trial is testingAlisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerWho this might be right forEstrogen Receptor StatusHER2/Neu NegativeInvasive Breast Carcinoma+6 more Mayo Clinic 96
Not applicableStudy completedNCT05673850What this trial is testingAssociation Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or ChemotherapyWho this might be right forBreast Neoplasms Peking University 518
Not applicableLooking for participantsNCT06548919What this trial is testingCurrent Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast CancerWho this might be right forESR1 Gene MutationAdvanced Breast Cancer SciClone Pharmaceuticals 450
Not applicableEnded earlyNCT03619044What this trial is testingThe Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.Who this might be right forHER2-positive Breast Cancer Institut Claudius Regaud 4
Testing effectiveness (Phase 2)Study completedNCT01050322What this trial is testingSafety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.Who this might be right forBRMS1Performance Status Zero to Two for Beginning the StudyPatient With a Maximum of One Chemotherapy+1 more Latin American Cooperative Oncology Group 142